Comparison of Pharmacokinetic Characteristics and Safety Between JW Amlodipine® Tablet 5 mg and Novarsc® Tablet 5 mg in Healthy Male Volunteers

Background: Amlodipine is a third-generation dihydropyridine calcium channel blocker, which has proven to be a useful drug against hypertension or angina.Methods: This randomized, open-label, two-period, two-treatment, single-dose, crossover study was conducted in twenty healthy male volunteers.Subjects were administered 5 mg of the test or reference formulation.After 2-week washout period, the other formulation was administered.Blood samples were collected up to 144 hours after drug administration, and plasma amlodipine concentrations were determined by validated liquid chromatography-tandem mass spectrometry.Drug safety was assessed using measurement of vital signs, physical examinations, laboratory test, electrocardiograms, and adverse event monitoring.Results: All subjects were completed this study.The geometric mean ratios of C max and AUC last were 1.078 (90 % CI, 0.968 -1.200) and 1.095 (90 % CI, 1.011 -1.186), respectively.There were no serious adverse events were reported by both formulations.Conclusion: This study showed the test and reference formulations had similar pharmacokinetics and safety profiles.